Sonoma Pharmaceu Stock Price, News & Analysis

Sonoma Pharmaceuticals (Nasdaq:SNOA) has established a distribution agreement with Daewoong Pharmaceutical, one of South Korea's largest pharmaceutical companies, to market and distribute Primocyn Skin Solution. This partnership aims to leverage Daewoong's expertise to enhance sales of Primocyn products, which utilize Sonoma's patented Microcyn technology. Notably, Daewoong generates over $1 billion in annual revenues. The collaboration is expected to open new sales channels for Sonoma's products in South Korea, where Primocyn has a history of sales.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced that its Microcyn^® Rx products have secured a Distribution and Pricing Agreement (DAPA) with the Defense Logistics Agency (DLA) through its partner, EMC Pharma. This DAPA allows EMC Pharma to distribute Microcyn^® products, which include wound care and dermatology items, to federal customers such as VA hospitals and the Department of Defense. The partnership enables Sonoma to tap into the U.S. government's extensive purchasing power, expanding its market presence significantly.

Sonoma Pharmaceuticals has launched a new line of office dispense products for skin care professionals, including Regenacyn Plus, Reliefacyn Plus, and Rejuvacyn Plus. These products are designed to enhance patient outcomes and convenience by allowing clients to purchase prescription-strength products directly from their dermatologists and medical spas. Sonoma's products utilize patented Microcyn technology, known for its healing and infection-fighting properties. This initiative aims to tap into the growing aesthetic procedure market while providing added revenue streams for practices.

Sonoma Pharmaceuticals (SNOA) reported a mixed financial performance for Q2 and six months ended September 30, 2022. Revenues for Q2 were $3.3 million, a decrease of 11% from $3.7 million year-over-year, while international sales grew by 18%. Gross profit improved to 40% from 33% due to increased production efficiency. Operating loss decreased by 24%, reaching $0.9 million. The total net loss before taxes for six months was $1.9 million, up from $1.2 million last year. The company is optimistic about future profitability driven by a successful transition to a distribution model.

Sonoma Pharmaceuticals (Nasdaq:SNOA) announced the launch of two dermatological products: Reliefacyn Advanced Itch-Burn-Rash-Pain Relief Hydrogel and Rejuvacyn Advanced Skin Repair Cooling Mist for over-the-counter use in the U.S. Reliefacyn targets symptoms of eczema and skin irritations, while Rejuvacyn aids recovery after cosmetic procedures. Both products emphasize natural formulation and efficacy in healing. CEO Amy Trombly highlighted the expansion of their consumer-focused product line to address common skin conditions. Products are available via the company’s website and distributors.

Sonoma Pharmaceuticals (NASDAQ:SNOA) announced its participation at the CPHI Conference in Frankfurt, Germany, from November 1-3, 2022. The company aims to expand its market presence in the European Union by seeking new partners for its dermatology products, including treatments for acne, atopic dermatitis, and scar management. Sonoma's products, known for their safety and effectiveness, leverage Microcyn® Technology to improve quality of life globally. CEO Amy Trombly emphasized the focus on establishing connections with pharmaceutical leaders to grow their European business.

Sonoma Pharmaceuticals (Nasdaq: SNOA) reported a 73% revenue increase from Q4 2022 and 8% from Q1 2022, with total revenues of $4.0 million for the quarter ended June 30, 2022. The company also reduced net loss by 19% to $0.9 million and saw a 44% decline in net loss per share. While gross profit margins lowered to 36%, Sonoma's focus on commercialization and expanding partnerships is expected to enhance future growth. The firm launched new products and expanded its distributor network, indicating robust international performance despite a drop in U.S. sales.

Sonoma Pharmaceuticals (Nasdaq:SNOA) has launched the MicrocynVS line of products specifically for veterinarians, aimed at addressing various animal health issues including wounds and infections. The products leverage patented Microcyn technology containing stabilized hypochlorous acid, enhancing healing processes in animals. A non-exclusive distribution agreement with DV Medical Supply has been established to roll out these products to over 700 veterinary offices across the U.S. MicrocynVS is expected to significantly improve veterinary care and reduce inventory costs for veterinarians.

Sonoma Pharmaceuticals (SNOA) reported Q4 2022 revenues of $2.3 million, a 7% increase from $2.2 million in Q4 2021. The net loss per share improved to $2.9 million, down 14% year-over-year. Operating expenses rose 20% to $3.2 million, primarily due to reconciliations related to the Rx dermatology divestiture. For the fiscal year, total revenue fell to $12.6 million, a $6 million decrease from $18.6 million in FY 2021. Cash reserves stand at $7.4 million, reflecting a strong balance sheet amid transitions toward profitability and growth.